MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-12-2026
Relmada Therapeutics EV/EBITDA Ratio 2011-2026 | RLMD
Annual EV/EBITDA Ratio Relmada Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -4.24 | -2.32 | -1.64 | -0.487 | -2.91 | -8.34 | -3.53 | -2.37 | -1.17 | -0.869 | -2.92 | -0.402 | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -0.402 | -8.34 | -2.6 |
EV/EBITDA Ratio of other stocks in the Drug manufacturers industry
| Issuer | EV/EBITDA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Endo International plc
ENDP
|
-2.32 | - | - | $ 28.9 M |  Irlanda |
 |
Evoke Pharma
EVOK
|
0.599 | - | - | $ 36.6 M |  USA |
 |
Cumberland Pharmaceuticals
CPIX
|
45.3 | $ 5.6 | -1.23 % | $ 83.2 M | USA |
 |
HEXO Corp.
HEXO
|
-0.524 | - | 2.45 % | $ 38.1 M |  Canada |
 |
Calliditas Therapeutics AB (publ)
CALT
|
2.61 | - | -0.1 % | $ 2.03 B |  Schweden |
 |
AcelRx Pharmaceuticals
ACRX
|
-0.504 | - | 7.5 % | $ 6.35 M | USA |
 |
DURECT Corporation
DRRX
|
0.585 | - | - | $ 50.1 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-1.21 | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-18.4 | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
-1.28 | - | 10.11 % | $ 58.2 M | USA |
 |
Alimera Sciences
ALIM
|
28.9 | - | - | $ 142 M | USA |
 |
Cronos Group
CRON
|
0.428 | $ 2.68 | -2.55 % | $ 1.03 B | Canada |
 |
Athenex
ATNX
|
-3.19 | - | -23.39 % | $ 1.76 M | USA |
 |
Harrow Health
HROW
|
69.4 | $ 37.64 | -0.03 % | $ 1.38 B | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-19 | - | - | $ 2.06 B |  France |
 |
Catalent
CTLT
|
-64.3 | - | - | $ 11.5 B | USA |
 |
Eagle Pharmaceuticals
EGRX
|
5.6 | - | -39.89 % | $ 27.7 M | USA |
 |
Canopy Growth Corporation
CGC
|
-4.28 | $ 1.0 | -0.99 % | $ 108 M | Canada |
 |
Organogenesis Holdings
ORGO
|
6.81 | $ 2.34 | -1.68 % | $ 297 M | USA |
 |
Pacira BioSciences
PCRX
|
29.6 | $ 22.99 | -1.58 % | $ 1.06 B | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
-4.16 | $ 1.09 | -0.91 % | $ 1.35 M | USA |
 |
Aurora Cannabis
ACB
|
66.7 | $ 3.04 | -1.3 % | $ 167 M | Canada |
 |
Solid Biosciences
SLDB
|
-3.47 | $ 7.14 | -1.11 % | $ 625 M | USA |
 |
Jupiter Wellness
JUPW
|
5.65 | - | - | $ 33.6 M | USA |
 |
Lannett Company
LCI
|
-4.72 | - | 1.15 % | $ 7.11 M | USA |
 |
OrganiGram Holdings
OGI
|
-4.08 | $ 1.06 | -1.85 % | $ 101 M | Canada |
 |
Tilray
TLRY
|
-46 | $ 4.98 | -2.73 % | $ 3.08 B | Canada |
 |
cbdMD
YCBD
|
-2.5 | $ 0.69 | -1.72 % | $ 2.78 M | USA |
 |
Evolus
EOLS
|
-9.74 | $ 6.73 | 3.38 % | $ 434 M | USA |
 |
Sundial Growers
SNDL
|
-1.27 | $ 1.42 | -2.74 % | $ 3.37 M | Canada |
 |
Emergent BioSolutions
EBS
|
5.32 | $ 8.32 | -0.83 % | $ 445 M | USA |
 |
Veru
VERU
|
-3.28 | $ 3.0 | -7.98 % | $ 43.9 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
0.799 | - | - | $ 193 M | Canada |
 |
Assertio Holdings
ASRT
|
28.1 | $ 23.48 | 0.04 % | $ 150 M | USA |
 |
ProPhase Labs
PRPH
|
-4.26 | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
-13.5 | - | - | $ 1.42 B | USA |
 |
Bausch Health Companies
BHC
|
8.84 | $ 5.06 | -1.94 % | $ 1.88 B | Canada |
 |
PetIQ
PETQ
|
9.82 | - | 1.64 % | $ 400 M | USA |
 |
Recro Pharma
REPH
|
47.3 | - | -4.76 % | $ 65.3 M | USA |
 |
OptiNose
OPTN
|
-5.28 | - | - | $ 1.08 B | USA |
 |
SCYNEXIS
SCYX
|
-1.64 | $ 4.23 | -0.35 % | $ 211 M | USA |
 |
PLx Pharma
PLXP
|
-1.84 | - | -27.8 % | $ 2.56 M | USA |
 |
Viatris
VTRS
|
157 | $ 16.48 | 1.04 % | $ 19.2 B | USA |
 |
Zomedica Corp.
ZOM
|
-0.0319 | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
0.644 | - | - | $ 55.5 M | USA |
 |
Rockwell Medical
RMTI
|
-17.3 | $ 0.62 | 0.35 % | $ 22.3 M | USA |
 |
Tricida
TCDA
|
-3.64 | - | - | $ 3.25 M | USA |
 |
China Pharma Holdings
CPHI
|
-6.14 | $ 0.71 | -6.82 % | $ 3.05 M |  China |
 |
TherapeuticsMD
TXMD
|
-6.57 | $ 2.2 | 20.88 % | $ 25.5 M | USA |